- $5.96bn
- $6.26bn
- $739.02m
- 48
- 21
- 83
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.07 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -35.21% | ||
| Return on Equity | -4584.47% | ||
| Operating Margin | -60.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 286.73 | 373.65 | 449.54 | 563.95 | 739.02 | 857.22 | 1,044.24 | 28.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Directors
- Helmy Eltoukhy CHM (42)
- Amirali Talasaz PRE (41)
- Michael Bell CFO (52)
- John Saia SVP (48)
- Craig Eagle OTH (53)
- Michael Wiley OTH (45)
- Ian Clark LED (60)
- Myrtle Potter DRC (62)
- Vijaya Gadde IND (46)
- Bahija Jallal IND (59)
- Meghan Joyce IND (37)
- Samir Kaul IND (47)
- Stanley Meresman IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 9th, 2011
- Public Since
- October 4th, 2018
- No. of Shareholders
- 47
- No. of Employees
- 1,999
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 123,421,441
- Address
- 3100 Hanover Street, PALO ALTO, 94304
- Web
- https://guardanthealth.com/
- Phone
- +1 6502907575
- Auditors
- Ernst & Young LLP
Upcoming Events for GH
Q1 2025 Guardant Health Inc Earnings Call
Guardant Health Inc Annual Shareholders Meeting
Q2 2025 Guardant Health Inc Earnings Release
Similar to GH
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Guardant Health share price?
As of Today at 20:58 UTC, shares in Guardant Health are trading at $48.30. This share price information is delayed by 15 minutes.
How has the Guardant Health share price performed this year?
Shares in Guardant Health last closed at $48.30 and the price had moved by +181.47% over the past 365 days. In terms of relative price strength the Guardant Health share price has outperformed the S&P500 Index by +159.81% over the past year.
What are the analyst and broker recommendations for Guardant Health?
The overall consensus recommendation for Guardant Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Guardant Health dividend yield?
Guardant Health does not currently pay a dividend.
Does Guardant Health pay a dividend?
Guardant Health does not currently pay a dividend.
When does Guardant Health next pay dividends?
Guardant Health does not currently pay a dividend.
How do I buy Guardant Health shares?
To buy shares in Guardant Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Guardant Health?
As of the previous close price of $48.30, shares in Guardant Health had a market capitalisation of $5.96bn.
Where are Guardant Health shares listed?
Here are the trading details for Guardant Health:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GH
What kind of share is Guardant Health?
Based on an overall assessment of its quality, value and momentum Guardant Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Guardant Health share price forecast for 2025?
The analyst consensus target price for shares in Guardant Health is $55.29. That is 14.47% above the last closing price of $48.30.
Analysts covering Guardant Health currently have a consensus Earnings Per Share (EPS) forecast of -$3.03 for the next financial year.
Find out moreWhat is the trend in the Guardant Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guardant Health. Over the past six months, its share price has outperformed the S&P500 Index by +148.21%.
As of the last closing price of $48.30, shares in Guardant Health were trading +41.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Guardant Health PE Ratio?
The Guardant Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $48.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Guardant Health?
Guardant Health's management team is headed by:
- Helmy Eltoukhy - CHM
- Amirali Talasaz - PRE
- Michael Bell - CFO
- John Saia - SVP
- Craig Eagle - OTH
- Michael Wiley - OTH
- Ian Clark - LED
- Myrtle Potter - DRC
- Vijaya Gadde - IND
- Bahija Jallal - IND
- Meghan Joyce - IND
- Samir Kaul - IND
- Stanley Meresman - IND